What is the recommended evaluation before selecting an antibiotic for a reported penicillin allergy?

• A. Avoid all beta-lactams and use macrolides.
• B. Obtain detailed history; consider cross-reactivity with penicillins and cephalosporins; consider skin testing or trial of a beta-lactam in low-risk cases depending on reaction history.
• C. Presume a true IgE-mediated allergy and always avoid penicillins.
• D. Conduct a drug challenge with penicillin without any assessment.

Answer: (B)

Understanding whether a reported penicillin allergy can safely guide antibiotic choice hinges on careful assessment of the reaction history and the potential for cross-reactivity with related beta-lactams. The best approach is to start with a detailed history: exactly what reaction occurred, when it happened, how it manifested (rash, hives, swelling, breathing problems, anaphylaxis), how it was treated, and whether it required emergency care. This helps determine risk level and whether penicillin or another beta-lactam might still be safe.

Next, evaluate cross-reactivity with cephalosporins and other beta-lactams. Cross-reactivity is largely influenced by shared side chains; many newer cephalosporins have low risk of reaction in people with penicillin allergy, especially when the reaction history was not severe. This informs whether a cefalosporin or related beta-lactam could be used safely if needed.

Skin testing for penicillin allergy is an option in many settings, particularly when the history suggests possible IgE-mediated allergy but not a history of life-threatening anaphylaxis. A negative skin test has a high negative predictive value and supports using penicillin or related beta-lactams under supervision.

In low-risk cases, a supervised drug challenge with a beta-lactam can confirm tolerance and expand antibiotic choices without exposing the patient to unnecessary risk.

Overall, this approach avoids unnecessary broad-spectrum alternatives and preserves effective penicillin-class options when it’s safe to do so, while reserving avoidance and alternative non-beta-lactams for truly high-risk histories.